Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Micurx Pharmaceuticals / Equity Capital Markets

<p>MicuRx Pharma is the fourth biotech company to file with Hong Kong Stock Exchange for a listing under the new rule. In this insight, we will look at the following topics:</p>
<ul>
<li>Two antibiotic products in the pipeline. The target treatment and progress of clinical trials.</li>
<li>The multidrug-resistant (MDR) market.</li>
<li>The issue with the antibiotic market.</li>
<li>The company's investors and shareholders.</li>
</ul>
<p>We will discuss the company's valuation in our next insight.</p>

MicuRx Pharma is the fourth biotech company to file with Hong Kong Stock Exchange for a listing under the new rule. In this insight, we will look at the following topics:

Two antibiotic products in the pipeline. The target treatment and progress of clinical trials.
The multidrug-resistant (MDR) market.
The issue with the antibiotic market.
The company's investors and shareholders.

We will discuss the company's valuation in our next insight.

MicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment